Good morning. My name is Eric and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's investor conference call. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. Please note this event is being recorded. I'll now turn the call over to Trama Bui, Halo Zyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.

Thank you, Operator. Good morning and welcome to Halo Zyme's Investor Conference Call. In addition to the press release issued earlier this morning, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Hale-Zum's President and Chief Executive Officer, who will provide an update on our business and provide preliminary 2025 revenue estimates in addition to an update to our 2026 to 2028 financial guidance. On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risk and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in the press release and slide presentation. I will now turn the call over to Dr. Helen Torley.

Thank you, Trom, and thank you all for joining us this morning. The fourth quarter, and specifically the month of December, was a standout period for Halazime. Never before have we executed on such a broad series of value-creating events in such a brief time. This execution is creating a value inflection for HalosM, unlocking multiple drivers of long-term, durable, and profitable revenue growth. I'm incredibly energized by the pace of progress, and I'm very confident in the path ahead. Let me turn now to slide three. Here is our agenda for today. I will begin with the 2025 highlights, which are summarized on slide 4. In 2025, we acquired two innovative, long-duration IP subcutaneous delivery enabling technologies. In November of 2025, we closed on the acquisition of Electrify, acquiring HyperCon, a novel, clinic-ready in 2026, biologic hyperconcentration technology with IP to the mid-2040s. And I am pleased to announce that in late December 2025, we acquired SurfBio, adding a second innovative biologic and small molecule hyperconcentration technology, also with long duration IP to the mid-2040s. These acquisitions broaden our opportunity to collaborate exclusively and non-exclusively across the full range of leading and emerging targets and mechanisms of action. We are creating the next waves of major SC innovation following Enhance, which will last over a very long-term time horizon. In parallel, in 2025, we continue to demonstrate strong Enhance momentum. Highlights include the global regulatory approvals for Enhance co-formulated with Johnson & Johnson's Blockbuster product, RybraVant. This resulted in 10 globally approved Blockbuster products now being commercialized with Enhance. And I am delighted to say that in late November and December, we signed three new enhanced collaboration agreements, signaling the recognition by Biopharma that enhances the gold standard for large volume, rapid, subcutaneous drug delivery. These three new agreements are a strong representation of the broad range of enhanced opportunities in discussion today, with participation by established large pharma and smaller biotechs, and with target profiles, including IV to subcutaneous conversion and subcutaneous extended dozing. You will note the continued broadening of therapeutic areas, too, now including obesity and inflammatory bowel disease, in addition to oncology. And I'm delighted to say that clinical planning has already kicked off for all three new collaboration Phase 1 study starts. Collectively, the 2025 events shown here create additional visibility and new revenue opportunity extending into the 2040s. Let me turn now to slide 5. Our growth from one to three subcutaneous delivery technologies, each of which is royalty bearing, capitalizes on and will help fuel the growing demand and trend for more subcutaneous delivery of drugs administered in the physician clinic and also in the patient's home. Moving to slide six, let me review how our technologies address the challenges pharma faces to date in creating biologics that can be given subcutaneously. This will allow you to appreciate how our broadened portfolio by providing tailored solutions to address each partner and product-specific needs so dramatically increases our opportunity. Beginning on the left, many biologics require high volume of injections to deliver the therapeutic dose due to the concentration and formulation limitations. As an example, the approved enhanced co-formulated partner products range from 5 milliliters to 23 milliliters volume of injection based on concentrations of 40 to 180 milligrams per ml. Now, it's important to just mention here that only about 2 milliliters can comfortably be injected subcutaneously in a single injection due to the structure of the subcutaneous space, which is filled with hyaluronin. Enhance is the perfect solution for this, enabling rapid, large-volume subcutaneous delivery by temporarily degrading the hyaluronin in the subcutaneous space, which results in volumes of 5 mLs being able to be given in as little as 30 seconds, as we see with 5GART Hytrula within hands, or 15 milliliters in 3 minutes, as we see with Darzlix Faspro within hands. Enhance has demonstrated an unmatched track record of regulatory and commercial success when combined with antibodies and bispecifics, where it has enabled drugs previously given intravenously to be given subcutaneously and extended the dosing interval of an already approved subcutaneous drug Hycuvia by allowing larger single doses to be administered. And let me just take a moment to also highlight two new growth trends to watch for that are related to Enhance that I am very excited about and where we are very busy in conversations with potential partners. The first is for use with nucleic acids where there is strong interest in whether Enhance can enable the subcutaneous delivery of lipid nanoparticle and large-volume nucleic acid conjugate formulations, while mitigating the inflammatory and immune responses usually seen with subcutaneous delivery. And the second is for use of enhanced with certain antibody drug conjugates, where there is interest in whether the change in the PK profile, and specifically the lower Cmax with an equivalent or greater AUC, can result in an improved risk-benefit profile. Now, for some disease conditions such as autoimmune, In neurology, nephrology, and cardiovascular diseases, patients and their physicians are seeking more rapid delivery options, including options that the patient can deliver at home. And this is where HyperCon and the CERF Bio hyperconcentration technology come in. Each technology, through a different, novel, patented approach, can lie high per concentration of the biologic up to 500 milligrams per ml, or three to four times higher on average than is possible today. This can result in much smaller volumes for injection, potentially less than 2 ml, or between 2 ml and 10 ml. Importantly, feasibility of approximately 500 milligrams per ml has been demonstrated for both of the technologies, including with monoclonal antibodies, pectides, and even small molecules, supporting the broad opportunity. Volumes in the range of up to 2 mLs will fit into a small-volume auto-injector, or 3 to 10 mLs into Halozyme's proprietary high-volume auto-injector, enabling quick, simple delivery in seconds given by the patient or a healthcare practitioner. Halozyme has become the one-stop shop for biopharma for subcutaneous delivery. Now you may be asking why do you need and why do you want two hyperconcentration technologies? Let me address that on slide 7. Strategically two technologies that work differently to hyperconcentrate therapeutics expand our opportunity and this is because we can offer partners tailored options to fit their needs and meet their target product profiles allowing them to select the approach that will be the best fit for their drug. It also allows us to work with more companies on leading and emerging top targets or mechanisms of action. As shown on the slide, the HyperCon technology achieves concentrations of approximately 500 milligrams per ml through a novel patented dehydration process. This is an advanced technology with feasibility demonstrated in tens of tests with different monoclonal antibodies and other treatment modalities. Based on the strong progress made in advancing manufacturing and clinical testing readiness, we are projecting that two current partners will initiate phase one studies with HyperCon by the end of 2026 or before. The CERF bio-hyper concentration technology also achieves concentrations of approximately 500 milligrams per ml. It achieves this through a combination of the use of a novel proprietary excipient that enables stable, dense, low friction particles and spray drying. Multiple experiments have demonstrated feasibility of achieving stable formulations at approximately 500 milligrams per ml, including with monofone antibodies and small molecules. With long-duration intellectual property to the mid-2040s for each technology and opportunities for patent life extension based on novel findings, each technology excitingly adds to Halosand's long-term and durable royalty revenue opportunity. With those 2025 business highlights, let me now review the 2025 projected financial results, which are shown on slide 8. I'm delighted to say that based on our preliminary revenue estimates, we expect to exceed our 2025 total revenue guidance and to achieve our 2025 royalty revenue guidance, compared with the guidance estimates that were last updated in November of 2025. We now expect total revenue of $1.385 billion to $1.4 billion, 36% to 38% growth over 2024. This is an impressive increase of $370 to $385 million year over year. This strong projected performance is predominantly driven by royalty revenue, which is projected at $865 million to $870 million, dollars a 51 to 52 percent increase and an almost 300 million dollars higher than prior year a truly outstanding performance i think you will agree and let me just mention that we are not providing the ebitda and non-gap eps update at this time as we're still pending the accounting determination and conclusion of the impact of the recent m&a transactions that i just discussed this information will be reported with the Q4 results. Let me move now to the 2026 guidance, which is shown on slide nine. I am very pleased to communicate that in 2026, a full one year earlier than the original projection, we project we will exceed $1 billion in royalty revenues. Recall I first provided this projection in January of 2018, projecting achievement of the $1 billion in royalty revenues in 2027. Many were sceptical at that time, wondering if we would navigate the then outsized concerns regarding patent cliffs in 2024 and 2027. You can see we came through this period very successfully, an important point to remember when I talk about our future growth drivers. I'm delighted to announce that based on the ongoing strength of our business, we are raising our 2026 guidance. We predict total revenue in 2026 of $1.71 to $1.81 billion, a 23% to 30% increase over our 2025 estimate, reflecting a $318 to $418 million year-over-year increase. This strong performance is driven by increased expectations for royalty revenue and product sales. Royalty revenue guidance is increased to $1.13 billion to $1.17 billion, a 30% to 35% increase year over year, and reflecting an additional $263 to $303 million versus prior year. Adjusted EBITDA and non-GAAP diluted EPS guidance are also increased from prior guidance ranges. I will highlight that non-GAAP diluted earnings per share is projected to be $7.75 cents to eight dollars and 25 cents a meaningful increase of a dollar and 25 cents above our prior guidance and i'll just note that the 2026 guidance does include approximately 60 million dollars of new operating expense for advancement of the two new hyper concentration technologies hypercon and servbio which were not included in our prior 2026 guidance let me turn now to slide 10. We're also very pleased to provide our updated and raised longer-term guidance for the period 2026 to 2028. I will focus you on total and royalty revenue and then on non-GAAP diluted earnings per share. In 2028, we project total revenue to exceed $2 billion, a remarkable projected growth from the $1 billion in total revenue that was achieved in 2024. This is largely driven by continued robust royalty revenue growth which is projected at 1.46 billion to 1.51 billion dollars in 2028 a 26 to 28 percent CAGR for the period 2024 to 2028. I will note that the 2028 royalty revenue projection does not include the potential U.S. manufacturing IP extension for Enhance which would we project have the impact of maintaining the royalties for Darzlix Fast Pro and Riber Rent Fast Pro at the original mid-single-digit royalty rate in the United States from September of 2027 to March of 2029. And non-GAAP earnings per share is projected to more than double from 2024 to 2028, projected at $10.50 to $11.10 in 2028, demonstrating the strength of our royalty business model and our strong fiscal discipline. I'll move now to slide 11 and just take a moment to highlight what truly differentiates our business. In two words, it is durability and profitability. We have expanded from one to three subcutaneous delivery licensing technologies, Enhance, Hypercon and Surfbio, that each bring recurrent, long-duration royalties. Importantly, each of these businesses is also asset light, with the partners responsible for development and commercialization costs. As a result of the asset light model and our strong operational efficiency and excellence, we project for the 2026 to 2028 period that our growth margin will exceed 80%. Our free cash flow will exceed 70% of our EBITDA, and operating margin will be greater than 60%. I will now turn to what excites me the most and what gives me such confidence in our future, our growth roadmap, beginning on slide 13. This roadmap provides the multiple growth drivers in 2029 and beyond that give me incredible confidence, just as I had in 2018, that we have the strategy, the levers, the opportunities, and the financial strength to create an incredible growth performance for Halozyme for many years to come. I will begin with Enhance. The updated revenue and royalty guidance for 2026 to 2028 is driven by our 10 approved products. Our approved products include Darsalex, which is in its 11th year post-initial launch and is still delivering a magnificent, greater than 20% year-over-year revenue growth with sales of $14.3 billion in 2025. Darzalix Fastpro with Enhanced today commands more than 90% share of total Darzalix sales and has been the key to this robust growth, enabling and expanding use of Darzalix in the large front and second-line multiple myeloma patient populations. Darzalix is a cornerstone to J&J's ambition to exceed $50 billion in oncology sales in 2030, and they have invested smartly in developing Dorothel X Fast Pro to demonstrate its unassailable risk-benefit profile in so many multiple myeloma indications that I and many believe it will continue its remarkable growth trajectory, delivering robust royalty revenue to Halazam for multiple years to come. A second Blockbuster SC product within hands I will highlight is Eugenics' by Barthay Trullo. Approved in two subcutaneous indications today, 2025 total sales were $4.15 billion, a 90% growth year over year. The mid-2025 launch of the pre-filled syringe, which includes enhanced-formulated five-car high-trulo and which enabled at-home and in-clinic subcutaneous delivery in as little as 30 seconds, was a key driver of this strong revenue performance and of the robust growth. With high opportunities still available in the currently approved subcutaneous indications and multiple future SE indications in development, we are excited for the continued growth of FiveGuard Hydrolo. Now, there are eight additional approved subcutaneous products with Enhanced, including six more recently launched and growing sub-Q with Enhanced products. These launched products represent substantial new royalty revenue opportunity for many years to come. And adding on top of this will be our development portfolio. For Enhanced, we anticipate six new products will enter into Phase I clinical testing in 2026, resulting in a total of 13 Enhanced development products. The development products have the potential to launch in the 2028 to 2031 timeframe, based on a number of factors, including when they entered Phase I testing and considering our historical timeline of approximately five years. Now, I will note that, excitingly, recent company innovations and FDA changes may support a three- to four-year development timeline in some cases, meaning an even shorter time to royalty revenues. And this is just a view from where we sit today. Following our strong 2025 performance with three new enhanced licensing agreements, interest from Biopharma has never been higher. As the gold standard for SC delivery of monoclonal antibodies, we continue to be approached by many companies. In addition to this, in response to data we have generated on the use of Enhance with nucleic acids and antibody perconjugates, we are fielding multiple incoming calls and gaining multiple meetings through our outreach to discuss how Enhance can improve the profiles of these newer treatment modalities. Based on this interest, I expect to sign between one to three new licensing agreements on Enhance this year, including with pharma and biotech companies. Importantly, with these new agreements, the Enhance royalty durability will extend into the 2040s. Moving now to slide 14, let me now turn to HyperCon. We acquired HyperCon through the acquisition of Electrify in November of 2025. Electrify has three signed licensing agreements to date, with Ergenics, Johnson & Johnson, and Lilly. We expect two partners to initiate Phase I clinical studies for already approved blockbuster drugs incorporating the HyperCon technology by the end of 2026 or earlier. Based on development timeframes, we project potential approval in the 2030-2031 timeframe. Excitingly, additional feasibility testing with additional drugs is ongoing and planned. And based on this, we see the potential for an additional three to five launches by the mid-2030s. Strategically, I also want to highlight that HyperCon also provides Halosyn with the opportunity to transition current partners from Enhanced to HyperCon. I mentioned earlier the increasing interest from patients and the healthcare practitioners for at-home, smaller-volume, rapid sub-q delivery. By applying a Halozyme hyperconcentration technology, current enhanced partners have the potential to significantly lower the volume of injection and enable delivery by auto-injector, further strengthening their competitive differentiation by meeting the patient and healthcare practitioner needs. For Halozyme, this could extend royalties at a mid-single-digit rate into the 2040s. With the opportunities I just outlined and Halozyme's subcutaneous development expertise, we see a path to Hypercom delivering approximately $1 billion in royalty revenues in the mid-2030s, or approximately five years after the first launches. As shown in slide 15, it's a summary of our expanded commercial and development portfolio. There will be an almost doubling of the number of commercial and development products, increasing from 19 total commercial and development products by the end of 2026 to 36 in 2028. Recalling my comments on a conservative, approximately five-year development timeline, this crystallizes the multiple new royalty revenue streams projected over the upcoming years. Now, the final and a very important growth driver is additional M&A, as is shown in slide 16. It is our goal to continue to evaluate drug delivery technology opportunities where we can leverage our strong expertise. And we will also seek to utilize and deploy our strong cash flow to add growing revenue businesses, adding assets and companies where Halosan can add to and accelerate the value creation. We project that our future acquisitions will add revenue extending into the 2040s and, importantly, could begin to add growing revenue in the nearer term. Let me move to our 2026 goals. 2026 will be another incredible year of execution. We project supporting six new enhanced products and two new HyperCon products to begin Phase I clinical studies, bringing our total products in development to 15. Further supporting momentum and success, current partners have multiple Phase 2 and Phase 3 data read-ups for their expanding the commercial opportunity. And it is our plan to deliver three or more new licensing agreements in 2026 with a projection of between one and three new enhanced deals and one to two hyper-con new deals. And we will also seek to complete additional acquisitions targeting strong revenue and margin growth opportunities. Let me close with a few reflections. I've been the CEO at HaloZime now for 12 years. In this time, HaloZime has successfully navigated multiple challenges and defied popular wisdom, delivering strong, repeated year-over-year growth. We have created a unique end-of-one business. I know this can make it more challenging to model, but the results are very evident. We cannot, due to contract obligations, always tell you the play-by-play. But what I want to leave you with today is that I know the play-by-play. I have a team that's delivered and will deliver again. And finally, that I have never been as confident or more excited in HaloZen's future. With that, Operator, we will open the call for questions, and I'll be joined by Nicole for the Q&A session.

At this time, I would like to remind everyone in order to ask a question, please press star, followed by the number one on your telephone keypad. Your first question comes from the line of Sean Laman with Morgan Stanley. Please go ahead.

Good morning, Helen and Nicole, and congratulations on such strong financial performance and strategic outlook. Helen, you mentioned a couple of things that are interesting. So the new Clay can assign ADC opportunities. I wonder if you could even ballpark that and give us your sense of what the opportunity might mean in terms of size and how that compares to your current business. And the other question is, you know, the transition potentially of enhanced products onto Hypercon. You know, could you give us a ballpark of what you think the opportunity there is, like how many products might be open to transition and how that might extend the IP runway? But thank you.

Thanks, John, for the questions. With regard to nucleic acids and ADCs, I can talk about that in terms of the numbers of products, because as you can well imagine, it's a growing and emerging field where if we try to look for analysts' projections or evaluate pharma, the numbers are pretty incomplete. But if you just think about all the announcements you see throughout 2025 of companies acquiring and companies advancing different types of ADCs and nucleic acids, I can say this is a very strongly growing class of product that is expected to be the predominant wave in years to come, diminishing over time the dominance of the antibodies. And so that's why we're so excited to be able to play in this new and emerging field. Our chief scientific officer, Chris Wall, has been generating data, engaging with tens of companies on this potential to see whether the profile of the products can be changed into basically an improved risk benefit or efficacy profile, depending on which modality we're talking about. And so, bottom line, Sean, it's an exciting area that is very rapidly growing. And we are delighted to be seeing the strong interest we have with so many incoming inquiries on it. With regard to HyperCon, you know, it's still pretty early in our days and our conversations. But what we wanted to highlight and make sure was visible to all of our investors is that the field of sub-Q delivery is evolving. And Enhance was a major, major innovation in terms of being able to allow patients to get rapid, high-volume sub-Q delivery. But the market is moving and the demand of the physicians and the patients and the pharma companies is really trying to get to more at-home therapy. And so we don't believe our partners will be static even with their exciting blockbuster drugs. They want to be able to have the best offering for patients. They want to be able to have the most competitive profile. And so it's not going to be a static field in our view. So it's a space for our investors to watch. And we're very excited about this potential evolution, which will just, as I mentioned in the call, add to the durability of our revenue potentially at the mid-single-digit rate.

Wonderful. Thank you. If I can just squeeze one more in. So you've given, I think, a billion-dollar royalty aspiration for Hypercon, I believe it was, into the 2030s, which is quite substantial. And then you've announced the acquisition of SurfBio, and you're implying that there's a fairly fertile ground there for further M&A. So fair to assume that maybe all these acquisitions are going to contribute more materially to what Enhance will into the 2030s. So Enhance might not be the dominant portion of your business.

You know, it's still very much our aspiration to continue to grow Enhance. And Sean, what I will say is, as you look at that, 15 total products that we're projecting in development at the end of 2026, 13 of those will be Enhance. And so Enhance is definitely with the three deals we signed at the end of last year, the ongoing conversations we're having this year and my expectation of between one to three new Enhance deals this year and the potential for partners to be moving more products into the clinic even as we speak, Enhance is still going to be a robust contributor. So that is absolutely our goal and will remain a very important platform for Halazime for many years to come. Adding to that, as you say, we've got Hypercon now, where we are projecting up to the billion dollars by the mid-2030s, and then M&A will be layered on top of that. And I think you're absolutely getting our message from today, which is Halazime has multiple growth drivers. And we have the financial wherewithal and the execution abilities to be able to pull all of these levers in parallel. And that's what got me so excited about the future and the future growth trajectory for Halozyme.

Wonderful. And thank you. And congratulations again, Helen.

Okay. Thank you.

Your next question comes from the line of Brendan Smith with TD talent? Please go ahead.

Great. Thanks for taking the questions, guys. And congrats on all the updates here. Really great to see. Maybe just quickly wanted to first ask about a little bit more on the relative strategy for implementing Electro-5 versus surf biotechnology. I guess, how should we really think about which areas, drugs, or types of partnerships are more likely to use each once they really kind of get their feet here? And then I just wanted to ask also about your commentary regarding FDA changes potentially expediting the development timeline for enhanced. Can you expand on that just a little bit more and if you see any read-through from some of those kind of helping to pass for Electrify or Surfbio? Thanks.

Yeah, thanks for the question, Brendan. And yeah, we're very excited to have the two hyper concentration technologies, which are working differently. And I think that's very important to remember because that means that they may be more suitable for one type of modality versus another. Each of them has demonstrated feasibility across a range of monoclonal antibodies and different protein and protein conjugates. And I will say Servbio has also demonstrated feasibility in the small molecules. And what we believe will happen and is already beginning to happen is partners will come to us and discuss their target product profile. Is this going to be delivered in the physician's office? Is it going to be delivered by a physician at home? Is it going to be delivered by the patient themselves? Then look at the actual formulation of the product and identify which of our technologies is going to be the best match to that profile. And by having the three technologies now, we'll be able to work with a broader range of companies. We'll be able to work across exclusive and non-exclusive targets. And I think you can see exactly how this so excitingly broadens the partners and the number of products that we'll be able to work on in the future. So hopefully that addressed your question with regard to that. And each of the technologies, it's our goal to continue this exciting model we have, which is asset light with the milestone and royalty collaboration style agreements. We have those for Enhance. You know that for Electrify, they were able to command very similar types of structure and royalties as to what we have done with Enhance, and we are projecting exactly the same with SurfBio. So it really will be based on a profile that partners can choose which one best fits their goals. The FDA changes, this has been in conversation over time, Sean, with regard to the technologies as we've now got over 1.3 million patients treated within hands globally. There's a lot more comfort in the safety profile. And we saw, as an example, the innovator Ergenics being able to have a phase three study in Mycena Gravis that was just approximately 100 patients large. And each of our partners now goes to the FDA and is introducing more and more innovative styles of studies. There's opportunities to not do large controlled phase three studies, perhaps doing more of an internal control, which can reduce the sample size. I think these designs will become public over the next months and years as current partners advance. And as we can talk about that in more detail, we'd be delighted to do so. But I think it's a nice reflection of the fact that Enhance has been and is the gold standard. And that's why the studies are getting more and more streamlined and creative and innovative. Translating that to Electrify and SurfBio, I think we'll go through the same profile where there might initially be some of the larger, more standard studies. a single large phase three study, for example, for approval of SurfBio or the HyperCon technology. But over time, I think there's going to be the same type of recognition that these studies can be more and more streamlined, especially if you're comparing it to an already approved drug. So we're delighted to partner and see some of the great ideas that are coming from our partners and supported by the excellent clinical team we have here at Halozyme.

All right, great.

Your next question comes from the line of Michael DeFior with Evercore ISI. Please go ahead.

Hey, guys. Thanks so much for taking my question, and congrats on all the progress. Two for me. Just HyperCon and SurfBio, could you maybe walk us through the key differences between the two technologies a little more? Like, I noticed that both technology platforms are able to formulate monoclonal antibodies. Why would using one tech platform for a monoclonal antibody be more suitable than the other? And at this stage of the game, is one technology more scalable than the other? And I have a follow-up.

All right. Thanks, Mike. Yes, getting down to the basics of how each of them works. They work quite differently with the surf bio being a polymer technology that lowers surface tension during the processing, which results in higher protein stability and the potential to obviously create these hyper-concentrated formulations up to 500 milligrams per ml. Hyper-con does exactly the same, achieving up to 500 milligrams per ml through a dehydration process. So each of them takes a different approach. And as I was mentioning earlier, what we see and expect, and certainly seems to be confirmed in early conversations, is depending on the particular molecule, and that would include monoclonal antibodies that our partners are wanting to hyperconcentrate, there may be one approach that is deemed to be more suitable from the get-go than the other one. And so the partners will be selecting, based on their formulation and their goals, exactly which of these technologies is going to be the best fit. We're very excited about the progress of these technologies. Obviously, HyperCon is the more advanced one. We're expecting two phase one studies to start in 2026. And we can say that Chase and the team have been doing an excellent job in getting everything ready, including the manufacturing, to be supportive of that. The SURF biotechnology is earlier. We're projecting being able to be in the clinic by the end of 2027, early 2028. And so we're going to be working on advancing the non-clinical recipient qualification, the GMP manufacturing. So probably a little bit early to be able to comment on relative scalability of one versus the other. but both of them offering a differentiated approach for partners to meet their target profiles.

Excellent. If I could just squeeze one follow-up that kind of just piggybacks on the previous question regarding potential accelerated timelines for FDA approval. If we assume that a buy was similar in hands were to come on the market after 2029, Given the fact that you said the FDA is very comfortable with Enhance, given its long historical safety profile, does that view from the agency still hold true with biosimilar versions of Or could the FDA make biosimilar versions of Enhance not have an accelerated timeline to approval? Thank you.

Let me just make a couple of comments about the likelihood of biosimilars coming first of all, Mike. We have co-formulation patents for the majority or expect co-formulation patents to be issued for the majority of our products. The actual co-formulation patents which relate to the combination of partner molecules with our RUPH20, we believe will be sufficient to preclude the ability for the biosimilars making an identical RUPH20 to launch. Now, that means then that a biosimilar company can't follow the exact same path we have, which does bring our expectation that a biosimilar company for an individual product would need to do a pretty full clinical development program, which would enable them to demonstrate to the FDA no risk of immunogenicity as well as comparability. And so for the biosimilar companies, it's not going to be a straightforward pathway because of the patent status of most of our partner product, as well as the FDA still wanting for biologics that demonstration, we believe, of no immunogenicity, which was a very important question, if you recall, for us to demonstrate over the years.

Thank you.

The next question comes from the line of Mohit Banzao with Wells Fargo.

Please go ahead. Okay. Thank you very much for taking my question and congrats on all the progress. So I have one detailed question. So excuse my naivety, but is there a potential for enhanced platform or any of these hypercon technologies to actually help out with the longer acting or making the drugs longer acting? Because from my read, it looks like Enhance actually increases the absorption and that could make it faster acting rather than longer acting. One thing like that, could you be in the GLP space making them longer acting or things like that? That's the part I want to understand. And then the second one is, is there any FTC risks with the surf bio deal given that there are some similarities here with Electro-5?

Yeah, thanks, Mohit. With regard to the longer acting, we are actually engaged with partners on being able to, and I'll call it extending the dosing interval, which is, I think, a similar concept. But it really comes down to within hands, you can deliver a larger dose and that larger dose, depending on what happens to the PK profile, can extend that time where it's delivering the efficacious levels in the blood. And so you can go from, as an example, a drug that's delivered every two weeks at a certain dose by being able to increase the dose in a single injection, extend that dosing interval, as an example, to four weeks. The best example we have of that in our portfolio is actually Hycuvia, where we are able to, with the ability to deliver up to more than 600 milligrams of immune globulin, have the patient treated every four weeks, whereas the IV is every three weeks. And if the patient was to have a sub-Q without in-hands, they would have to have multiple smaller injections because obviously you can't put in as large a volume. And so the concept is commercially available as Hycuvia, and we do have certainly partners talking with us about that today, being able to get from that two weeks to four weeks as an example, or even four weeks to eight weeks. So it doesn't make it longer acting, but it does extend the dosing interval. With regard to the FTC, the Electrify acquisition did undergo a standard HSR review, a period in that time expired, and we were able to move forward and close the transaction. And for the SURF bio, it isn't subject to FTC review because of the size of the entity.

Got it. Thank you very much, Ellen.

The next question comes from the line of David Riesinger with Leerink Partners. Please go ahead. Yes.

Thanks very much. So, congrats on the financial updates, Helen. I had two questions, please. First, you had set initially the 2028 targets back in 2024. So can you comment on why you're not rolling annual targets out to 2030 today? And then second, I believe there was an additional Darzalex formulation patent, a hyaluronidase patent, issued late last year. Could you, so considering that, could you remind us about what you are expecting for the timing of the conclusion of Darzilek's U.S. royalties in the 2030s and Darzilek's ex-U.S. royalties in the 2030s? So what is the timing for each of those to go to zero in the 2030s? I'm curious, and I'm just curious if that's changed at all. Thank you.

All right. Well, let me ask Nicole to address the guidance. And I think, David, you'll agree there's not a lot of companies give five-year guidance. There's not a lot of companies give three-year guidance even. But, Nicole, talk about the future.

Yeah, as Helen mentioned, we are pleased that we're able to give this multi-year view that, again, many companies don't do. And this is because we really focus on the 10 products that are globally approved today. But when we look at beyond 2028, and as we outlined a lot of those growth potentials today, is because we see so many drivers beyond 2028. So we know we have the expectation of 15 products that are in development with Enhance, the potential we talked about with the HyperCon technology to achieve a billion dollars in royalty revenue in that time horizon. And again, adding on the opportunity we have with our strong cash flow projections to continue to grow with additional royalties and our revenue, high growth revenue, high margin businesses with the addition of M&A are all the growth drivers that we see beyond 2028.

Thanks, Nicole. And with regard to the duration of the royalty term with J&J for Darzalex, just to be very clear in that, our current royalty term is projected to end in 2032 for both US and the EU. However, it's really important to consider this will be at that time an $18, $19 billion brand for J&J, which is almost all sub-Q at that time. We do expect in the upcoming years to be entering into additional conversations with J&J to continue to expand our relationship with them. When you think about the importance of that product, and especially it's a cornerstone to their $50 billion ambition, it's going to be very important that they do not have any discontinuity or risk to that. And so I wouldn't think about their revenue disappearing, David, as you suggested there. I think they'll be in our mutual interest to come forward with another type of agreement. It wouldn't be exactly the same, I don't think, as the one we have today. But that certainly is in our ambitions and plans that we continue durable revenue with Darzalex for years to come after the current expiry of the current licensing term. And put yourself in their shoes, I think, and you'll see that that's in their very good interest as well.

Thank you. Your next question comes from the line of Jason Butler with Citizens JMP. Please go ahead.

Thanks for taking the questions, and congrats on the results today and the acquisition. Two for me. Can you maybe, Helen, talk about to what extent the more recently approved products like Acrevas, Zenovo, and Teccentric, Hybrisa contribute to guidance in 26 and beyond? And just how do you think about the biggest royalty growth drivers over the next couple of years? And then second for me, obviously, you've now acquired two companies that are a clear strategic fit. But how do you think about prioritizing future potential acquisitions, both in terms of timing and business strategy?

That's great.

Well, I'll ask Nicole to talk about the color of the royalties and the contributions moving Yeah, the new term, and especially in 2026, the biggest drivers will continue to be the three largest drivers that we see currently, which is really focused on Darzilex, Fesco, and VivGart. But as you mentioned, the four more recently launched products are growing in contribution in 2026, and then certainly in future years as well are contributing to that growth that you see year over year.

Yeah, and when we have our Q4 call, I think we'll be able to talk a little bit more about that as our partners do make more comments. There were some comments made at JPMorgan, but we do expect to be able to provide more color, particularly on Okravis and Abdivo, where the presenters at JP Morgan were certainly speaking very enthusiastically as to the pattern of growth that we're seeing there. On M&A, Jason, you know, absolutely, these were a very strong strategic fit for us, being focused on the ability to expand our drug delivery offerings. As I mentioned in my prepared remarks, we also are expanding to also look at opportunities where there is a business that is growing and where Halozyme can see a path to us delivering more value. Now, what's important as you think about that is that could bring potential nearer term revenues for it that grow into the future and further add to what's already a very exciting growth story over the next five, seven, ten years and so we think about that having our eyes very much on the bull in both of those areas but very much the I think the new news today is just an excitement about potential opportunities to add growing revenue and margin businesses.

Great, thank you. The next question comes from the line of Corrine Johnson with Goldman Sachs. Please go ahead.

Maybe you could talk a little bit, given the SURF technology is preclinical, what they've shared in terms of immunogenicity and also, you know, what they shared that got you comfortable stepping in to make this acquisition at the time. I know with Electrify, it was that they were, you know, entering the clinic. So curious what you saw with the SURF technology here.

Yeah, thanks, Corinne. Yeah, very excitingly, You know, when we think about this, the SURF technology is a couple of years behind the Hypercon technology, but have followed a very similar path of engaging with multiple pharma companies to demonstrate the feasibility of being able to create these stable 500 milligram per ml high syringability formulations. And so, you know, that was obviously the very first thing. There is an early and initial, but absolutely appropriate for the stage of development, toxicology work that's been completed extremely well. And in terms of the manufacturing, that also has been set up in a way that impressed us and gives us confidence as to this being able to be progressed to be clinic ready by the end of 2027 or in 2028. So very nice overall package, recognizing it was earlier, and obviously the difference in the acquisition price, I think very nicely highlights the opportunity we have here to create value with SurfBio over the next couple of years as we advance it to the clinic.

I think you mentioned a billion in hyper-con royalties by 2035 or mid-2030s. Does that include partnerships beyond the three they've already established? and how did you think about kind of quantifying that guide?

Yeah, so, you know, obviously we have a very clear line of sight as to how we will get there. We can't provide details on the play-by-play just due to partner confidentiality, but I'll point you back to some of the comments I made in the prepared remarks, Corinne, to say that, you know, we're expecting two products to enter the clinic this year, and based on ongoing feasibility testing, the possibility of an additional three to five launches over the next several years after that. And it really is that pattern of engagement and progress that gives us that line of sight. Thank you.

Your last question comes from the line of Michael Obodai with HCW. Please go ahead.

Good morning. Congrats on a strong year. Mike on Formitra Kapoor. I have a two-part question. First, you raised the 2026 guidance by 20% at the midpoint and signed three new enhanced agreements. Is this raise capturing those contributions, or does it still reflect the conservative floor that you've previously guided to?

And also, now that you have two hyper-concentration platforms, is there a specific viscosity or volume threshold that dictates when a partner would choose surf bio over hypercon and how to do economics compared to the standard and hands and hands royalty thank you all right i'll tackle the second one and then i'll ask nicole to talk about the the guidance raise and you know we still are i i think um um mike at the experimental stage um with the surf bio so can't really talk about um any limits to the viscosity or volume and what i can say that has been remarkable and was very striking to our teams as we were doing our diligence is that up to this 500 milligram per ml concentration I talked about, the viscosity is incredibly low. The syringability is like, as my team described it, like injecting water. So I think that's the important thing to think. We're not trying to reach the limits of viscosity. We're trying to create highly concentrated molecules that don't have viscosity. And both of these technologies in the non-clinical area have demonstrated that very beautifully. Based on what's publicly available with regard to the Electrify HyperCon contract terms, those are very similar to Enhance. And it certainly will be our expectation. There are no collaboration and licensing agreements yet for the SURF biotechnology, but I can say that we would expect it to be in a similar range to what has been publicly announced with Enhance and also with the HyperCon technology. Nicole, can you address that question?

Yes, so with respect to 2026, the raise from our previous guidance really is driven by royalties and the strong trajectory we've seen with the top three drivers from Darzalex, Fesco, and VivGuard iTrulo. And then also you'll see that we increased our expectations for product sales, which is driven by increased expectations for our sale of API to our partners. And you mentioned the new collaborations. That really had an impact in 2025. As you see, we did increase our expected range for 2025 collaboration revenue. That's driven by upfront revenues received. And then the go-forward contribution will be more modest compared to our current products as those products continue to move through development.

Great. Thank you very much.

Nicole, there was one other question that came in as a write-in question that maybe I'll ask you to just address. Could you say more as to why you haven't reported exactly what accounting treatment is going to be addressing ServBio? And what are the ranges and choices there and any implications we should know about?

Yeah, and you'll all have seen that in our 2025 preliminary results, we did say that EBITDA and non-GAAP BPS will be reported in February when we report our final results for the quarter. And that is because we're working through the accounting treatment. We're working with our advisors on that as part of closing our year in financials. And the different treatments really come down to whether they are accounted for as a business combination or an asset acquisition. And a business combination being what you've seen us do in the past where really the acquisition and the assets are on your balance sheet. But in the event that there is an asset acquisition of IPR&D, you may have seen other companies where that is recorded as a one-time P&L charge. And that could be the impact of the SURF biotechnology being in the preclinical development stage. And so if that is the case, you will see a one-time charge in the fourth quarter of 2025, and that will be reflected in our EBITDA and non-GAAP EPS results in 2025. Thank you.

Thank you, Nicole.

There are no further questions at this time. Ladies and gentlemen, this concludes today's call. Thank you all for joining, and you may now disconnect.